

Who is BardyDx?

- Bardy Diagnostics, Inc. (“BardyDx”) is an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac monitors in the industry.
- BardyDx has FDA 510(k) clearance and CE Mark approval to market the Carnation Ambulatory Monitor (CAM) Patch.
- BardyDx generates revenue through sales of the CAM Patch and ECG analyses of the CAM (covered commercially by existing CPT codes)

What is the Carnation Ambulatory Monitor?

- Non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance with its lifestyle-enabling patch design.
- Designed to be worn comfortably and discreetly for up to 14 days by men, women, and children (suitable for pediatric patients >22 lbs).
- Placed on the center of the chest, directly over the heart for optimal ECG signal collection.
- Distinguished from other products by its state-of-the-art sensing technology, the CAM provides optimal detection and clear recording of the entire ECG waveform, especially the P-wave, the part of the signal that is essential for accurate arrhythmia diagnosis.



Problems with Current Cardiac Monitors

The current standard of care is the Holter monitor, which was introduced into clinical practice in the mid-1960s, lacks the sensitivity for comprehensive cardiac rhythm analysis due to its poor detection of the entire ECG waveform, particularly the P-wave:


1. Unreliable Diagnostics Lead to Repeat Testing

- 4 of 5 Holter tests fail to detect clinical events or diagnose disease.¹
- Approximately 23% will undergo repeat monitoring.²

2. Incomplete Diagnostics Result in Ineffective Therapies

- Inaccurate or incomplete detection provided by current monitors contributes to the decreased success rate of cardiac ablation procedures and medications.
- For example, 5-year outcome studies have shown a recurrence of atrial fibrillation (AF) in more than 60% of patients undergoing ablation therapy³ likely due to other underlying arrhythmias missed by current monitors.


Mobile Cardiac Telemetry
0.7MM Tests



**US Ambulatory Cardiac
Monitor Market⁴**
(\$1B)

The Solution: BardyDx CAM Patch

The CAM is the industry's only P-wave centric ambulatory cardiac monitor and arrhythmia detection device, designed to address the limitations of current products on the market.



Value Proposition



Clarity for Physicians

- Patented P-wave centric ECG detection technology designed to drastically improve clinical decision-making
- Demonstrated in head-to-head studies to be superior to current products:
 - 3.8x increase in clinically-significant arrhythmias compared to a Holter⁵
 - 40% more arrhythmias than the first-to-market iRhythm Zio Patch⁶



Convenience for Practices

- Simple-to-use, disposable patch avoids headaches with coordinating Holter lending & returns
- Fits into existing workflows, including option to perform ECG analysis in-house or outsource to BardyDx
- Strong practice applications in cardiology, emergency medicine, neurology (stroke), internal medicine, pediatrics



Comfort for Patients

- Improved patient compliance with its lifestyle-enabling patch design (no need to remove while showering or sleeping)
- Patient-friendly design that is discreet, compact, and comfortable
- 96% of patients preferred wearing the CAM patch compared to a 3-lead standard Holter monitor⁶



Gust Bardy, MD

Founder & CEO

- 38 years as a cardiac electrophysiologist
- 400+ peer-reviewed publications
- 240+ US Patents
- Founder of Cameron Health's (acquired by Boston Scientific) revolutionary S-ICD device

Executive Team

Gust H. Bardy, MD: CEO
Ken Nelson: CCO
Ed Vertatschitsch: COO
Mark Handfelt: CAO
Mark Query: CFO

Board of Directors

Gust H. Bardy, MD
Garheng Kong, MD, PhD
Alan Levy, PhD
Paul LaViolette
Dave Tamburri
Rik Vandevenne
Warren Watson

¹ Steinberg J, et al. 2017 ISHNE-HRS Expert Consensus on Ambulatory ECG and External Cardiac Monitoring/ Telemetry. *Heart Rhythm*. 2017;14(7).

² Arnold R, et al. Cost Analysis and Clinical Outcomes of Ambulatory Care Monitoring in Medicare Patients: Describing the Diagnostic Odyssey. *Journal of Health Economics and Outcomes Research*. 2015;2(2):161-9.

³ Bunch T, et al. Five-Year Outcomes of Catheter Ablation in Patients with Atrial Fibrillation and Left Ventricular Systolic Dysfunction. *Journal of Cardiovascular Electrophysiology*. 2015;26(4):363-370.

⁴ Braccideita, E. Ambulatory Electrocardiography Monitoring Devices – 2019 US Market Analysis. Decision Resources Group. 2018.

⁵ Smith W, et al. Comparison of diagnostic value using a small single channel, P-wave centric sternal ECG monitoring patch with a standard 3-lead Holter system over 24 hours. *Am Heart J*. 2016;185:67-73.

⁶ Rho R, et al. Comparison of two ambulatory patch ECG monitors: The benefit of the P-wave and signal clarity. *American Heart Journal*. 2018;203:109-117.